全文获取类型
收费全文 | 29908篇 |
免费 | 3201篇 |
国内免费 | 83篇 |
专业分类
耳鼻咽喉 | 229篇 |
儿科学 | 1010篇 |
妇产科学 | 1085篇 |
基础医学 | 4057篇 |
口腔科学 | 922篇 |
临床医学 | 3297篇 |
内科学 | 6357篇 |
皮肤病学 | 408篇 |
神经病学 | 2677篇 |
特种医学 | 1210篇 |
外科学 | 3740篇 |
综合类 | 582篇 |
一般理论 | 44篇 |
预防医学 | 3156篇 |
眼科学 | 501篇 |
药学 | 2510篇 |
中国医学 | 16篇 |
肿瘤学 | 1391篇 |
出版年
2021年 | 430篇 |
2020年 | 296篇 |
2019年 | 456篇 |
2018年 | 487篇 |
2017年 | 396篇 |
2016年 | 421篇 |
2015年 | 453篇 |
2014年 | 675篇 |
2013年 | 916篇 |
2012年 | 1299篇 |
2011年 | 1359篇 |
2010年 | 711篇 |
2009年 | 732篇 |
2008年 | 1205篇 |
2007年 | 1414篇 |
2006年 | 1285篇 |
2005年 | 1294篇 |
2004年 | 1246篇 |
2003年 | 1170篇 |
2002年 | 1129篇 |
2001年 | 1001篇 |
2000年 | 1080篇 |
1999年 | 938篇 |
1998年 | 359篇 |
1997年 | 307篇 |
1996年 | 315篇 |
1995年 | 338篇 |
1994年 | 284篇 |
1993年 | 283篇 |
1992年 | 721篇 |
1991年 | 714篇 |
1990年 | 680篇 |
1989年 | 639篇 |
1988年 | 610篇 |
1987年 | 622篇 |
1986年 | 595篇 |
1985年 | 543篇 |
1984年 | 480篇 |
1983年 | 384篇 |
1982年 | 295篇 |
1981年 | 237篇 |
1980年 | 224篇 |
1979年 | 379篇 |
1978年 | 347篇 |
1977年 | 246篇 |
1976年 | 251篇 |
1975年 | 257篇 |
1974年 | 279篇 |
1973年 | 233篇 |
1972年 | 261篇 |
排序方式: 共有10000条查询结果,搜索用时 126 毫秒
1.
Well‐being,health and fitness of children who use wheelchairs: Feasibility study protocol to develop child‐centred ‘keep‐fit’ exercise interventions
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
2.
3.
4.
5.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献
6.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
7.
8.
9.
10.
Facundo Davaro Jacob Roberts Allison May Coleman McFerrin Sameer Siddiqui Zachary Hamilton 《Journal of robotic surgery》2020,14(3):447-454
Partial nephrectomy is the mainstay of treatment for localized kidney cancer. A proportion of patients are upstaged post-operatively to locally advanced di 相似文献